Evidence map›Paper›PMID 41198680›Full record

ArticleNature communications2025

A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens.

Mia Urem, Annemieke H Friggen, Nina Musch, Michael H Silverman, Christopher J Swain, Michael R Barbachyn, Lawrence I Mortin, Xiang Yu, Robert J DeLuccia, Meindert H Lamers and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mia UremLeiden University Center of Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-8259-3991
Annemieke H FriggenLeiden University Center of Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.
Nina MuschLeiden University Center of Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0009-0006-8713-0888
Michael H SilvermanAcurx Pharmaceuticals, Inc., Staten Island, NY, USA.ORCID http://orcid.org/0000-0002-6651-646X
Christopher J SwainAcurx Pharmaceuticals, Inc., Staten Island, NY, USA.ORCID http://orcid.org/0000-0002-9636-4567
Michael R BarbachynCalvin University, Grand Rapids, MI, USA.
Lawrence I MortinAcurx Pharmaceuticals, Inc., Staten Island, NY, USA.ORCID http://orcid.org/0000-0002-7653-4135
Xiang YuAcurx Pharmaceuticals, Inc., Staten Island, NY, USA.
Robert J DeLucciaAcurx Pharmaceuticals, Inc., Staten Island, NY, USA.ORCID http://orcid.org/0000-0003-0802-2151
Meindert H LamersDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands. m.h.lamers@lumc.nl.ORCID http://orcid.org/0000-0002-4205-1338
Wiep Klaas SmitsLeiden University Center of Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands. w.k.smits@lumc.nl.ORCID http://orcid.org/0000-0002-7409-2847

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) NEMI (184.034.014)
6 · The paper itself

Abstract

Infections with antimicrobial resistant pathogens are a major threat to human health. Inhibitors of the replicative polymerase PolC are a promising novel class of antimicrobials against Gram-positive pathogens, but the structural basis for their activity remains unknown. The first-in-class PolC-targeting antimicrobial, ibezapolstat, is a guanine analogue in late-stage clinical development for the treatment of Clostridioides difficile infections, and related inhibitors are being developed for systemic treatment of infections with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Here, we present the cryo-electron microscopy structures of Enterococcus faecium PolC bound to DNA and in complex with ibezapolstat or the previously-undescribed inhibitor ACX-801. Both inhibitors form base-pairing interactions with the DNA in the active site, thereby competing with incoming dGTP nucleotides. We identify a crucial susceptibility determinant in PolC that is conserved in other organisms, such as C. difficile. This is explained by an unusual non-planar conformation of the inhibitors that induce a binding pocket in PolC. By combining structural, biochemical, bioinformatic and genetic analyses, this work lays the foundation for the rational development of an innovative class of antimicrobials against Gram-positive priority pathogens.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsDNA-Directed DNA PolymeraseEnterococcus faeciumEnzyme InhibitorsClostridioides difficileCryoelectron MicroscopyHumansMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsBacterial ProteinsDNA-Directed DNA PolymeraseEnzyme Inhibitors

Identifiers

PMID41198680
PMCPMC12592400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.